Shares of AstraZeneca PLC (NASDAQ:AZN – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $80.00.
A number of research analysts have issued reports on AZN shares. Morgan Stanley started coverage on shares of AstraZeneca in a report on Tuesday, January 23rd. They issued an “overweight” rating on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, Jefferies Financial Group lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd.
Get Our Latest Stock Analysis on AstraZeneca
Institutional Trading of AstraZeneca
AstraZeneca Price Performance
Shares of NASDAQ AZN opened at $70.85 on Friday. The stock has a market cap of $219.67 billion, a price-to-earnings ratio of 36.90, a PEG ratio of 1.26 and a beta of 0.50. AstraZeneca has a 52 week low of $60.47 and a 52 week high of $76.56. The company’s 50-day moving average price is $66.62 and its 200 day moving average price is $65.92. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.57.
AstraZeneca (NASDAQ:AZN – Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The business had revenue of $12.02 billion during the quarter, compared to analyst estimates of $12.07 billion. AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. AstraZeneca’s revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.69 earnings per share. As a group, research analysts forecast that AstraZeneca will post 4 earnings per share for the current fiscal year.
AstraZeneca Increases Dividend
The company also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were given a $0.965 dividend. This is an increase from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date was Thursday, February 22nd. This represents a yield of 2.3%. AstraZeneca’s dividend payout ratio (DPR) is 100.52%.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
- Five stocks we like better than AstraZeneca
- Insider Trading – What You Need to Know
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.